Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Incyte Files for U.S. Approval of Cancer Drug

By Drug Discovery Trends Editor | June 8, 2011

NEW YORK (AP) – Incyte Corp. filed for marketing approval of its lead drug candidate ruxolitinib, and has asked regulators to make a decision on the cancer treatment by early December.

The company said on June 6 that it asked the FDA to approve ruxolitinib as a treatment for myelofibrosis, a cancer of the blood. Incyte requested a priority review, and if the FDA grants that review, it will return a decision in six months instead of the usual 10 months. Priority reviews are given to drugs that treat diseases with limited or no treatment options, and Incyte said there are no drugs approved to treat myelofibrosis.

Novartis AG, Incyte’s partner on the drug, has said it will file for approval in the European Union by the end of June.

The company also reported new data from late-stage trials of ruxolitinib at the American Society of Clinical Oncology conference earlier this month. Analysts said on June 7 that the details are encouraging: Anemia has been one of the most common side effects of ruxolitinib in clinical trials, but Incyte said the rates of severe anemia went down over time. After 24 weeks of treatment, patients on ruxolitinib were about as likely to have severe anemia as patients who were only receiving standard treatments.

Thomas Wei, a Jefferies & Co. analyst, said the rates of anemia are high, but patients who were treated with ruxolitinib were less likely to need blood transfusions than other patients. He added that patients who had severe anemia still had strong improvement in their symptoms.

The initial results from the trials were reported in December and March.

The Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50